UK markets close in 3 hours 54 minutes
  • FTSE 100

    7,214.47
    -19.56 (-0.27%)
     
  • FTSE 250

    22,955.41
    -28.83 (-0.13%)
     
  • AIM

    1,234.50
    +5.40 (+0.44%)
     
  • GBP/EUR

    1.1847
    +0.0062 (+0.52%)
     
  • GBP/USD

    1.3737
    +0.0060 (+0.44%)
     
  • BTC-GBP

    44,683.69
    +13.26 (+0.03%)
     
  • CMC Crypto 200

    1,438.04
    +62.82 (+4.57%)
     
  • S&P 500

    4,471.37
    +107.57 (+2.47%)
     
  • DOW

    35,294.76
    +916.96 (+2.67%)
     
  • CRUDE OIL

    83.55
    +1.27 (+1.54%)
     
  • GOLD FUTURES

    1,764.00
    -4.30 (-0.24%)
     
  • NIKKEI 225

    29,025.46
    +474.56 (+1.66%)
     
  • HANG SENG

    25,409.75
    +78.75 (+0.31%)
     
  • DAX

    15,500.18
    -87.18 (-0.56%)
     
  • CAC 40

    6,674.53
    -52.99 (-0.79%)
     

Why Cara Therapeutics Shot Higher Today

·1-min read
Why Cara Therapeutics Shot Higher Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Cara Therapeutics (NASDAQ: CARA) was a hot stock on Tuesday. One of the formerly clinical-stage biotech's drug candidates won FDA approval, and investors reacted in the usual manner. The biotech company's most promising drug, Korsuva --- developed with Switzerland-based Vifor Pharma -- addresses this medical challenge sufficiently to win that all-important FDA approval.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting